Journal: bioRxiv
Article Title: Focused Ultrasound Thermal Ablation and CD40 Agonism Reprograms Breast Tumor Immunity to Drive Regression and Memory
doi: 10.64898/2026.03.02.708396
Figure Lengend Snippet: (A) CAD rendering of custom ultrasound-guided FUS system consisting of a 4-element 3.78 MHz transducer axially co-registered with 15 MHz MicroScan linear ultrasound imaging array. (B) Representative partial ablation scheme and (C) B-mode ultrasound images of E0771 tumor either before/during (top) or after (bottom) T-FUS treatment, with hyperechoic signature present after treatment (arrow). (D) Custom grading scale of presence of hyperechoic signal post-T-FUS treatment across all murine breast cancer models. (E) Overview of experimental timeline. (F) Representative H&E staining, along with cleaved caspase 3, PARP, and HSP70 staining, was performed on control and T-FUS-treated E0771 tumors 24 hours post-treatment. (G) In vivo surrogate measurements of ATP levels via bioluminescence at 10 minutes after T-FUS. (H) Temporal radiance curve (proxying relative ATP levels) for a sham vs. tumor volume-matched T-FUS mice (E0771 model). Significance assessed by Wilcoxon rank-sum test. **p=0.0028. H-L) (I) Percentage of B cells (CD19 + , MHCII + ), (J) macrophages (MФs; F480 + , Ly6C - ), (K) cDCs (CD11c + , MHCII + ), (L) monocytes (F480 + , Ly6C + ), and (M) granulocytes (CD11b + , Ly6G + ) out of CD45+ cells in the tumor. Significance assessed by Welch’s T-test.*p < 0.05, **p < 0.01, and ***p < 0.001 vs. control, respectively.
Article Snippet: The system was powered by a 200W amplifier (Electronics & Innovation 1020L) driven by an arbitrary function generator (Tektronix AFG3022C), and axially co-registered to a 15 MHz MicroScan linear ultrasound imaging array (MS200; VisualSonics).
Techniques: Imaging, Staining, Control, In Vivo
